MEGAN DINGUS: Open Payments
NPI 1548701279 · FRUITLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$498 in 22 payments from 11 companies in 2025. Trend: 2023 $410 · 2024 $1,180 · 2025 $498
Food & beverage: $498
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $139 |
| Otsuka America Pharmaceutical, Inc. | 1 | $89 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Neurocrine BioSciences, Inc. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| Alkermes, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
Products named: VRAYLAR, REXULTI, HETLIOZ, INGREZZA, Qelbree, ARISTADA, UZEDY, Auvelity.
Industry payments across MD — which companies pay providers there.
